menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Cardiac Myosin Inhibitor Reduces Need for Septal Reduction Therapy in Obstructive HCM

ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Comments
  • Overview

    Dr. Milind Desai discusses the design and results of the VALOR-HCM trial, which demonstrated that mavacamten reduced the need for septal reduction therapy at 16 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). 

Facebook Comments

Recommended
Details
Comments
  • Overview

    Dr. Milind Desai discusses the design and results of the VALOR-HCM trial, which demonstrated that mavacamten reduced the need for septal reduction therapy at 16 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). 

Facebook Comments

Schedule26 Jun 2022
Webpack App